Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: Differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17

Cytokine

Volumn 64, Issue 1, 2013, Pages 234-242

  Ashlin, Tim G ^a   Kwan, Alvin P L ^a   Ramji, Dipak P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

ADAMTS proteases; Atherosclerosis; Cytokines; Gene expression; Macrophages

Indexed keywords

ADAMTS1 PROTEIN; AGGRECANASE 1; AGGRECANASE 2; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; PROTEIN TL1A; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS; ADAMTS; ADAMTS PROTEASES; APOB; APOE; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATHEROSCLEROSIS; CYTOKINES; DEATH RECEPTOR 3; DR3; ECM; EXTRACELLULAR MATRIX; GAPDH; GENE EXPRESSION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HMDM; HUMAN MONOCYTE-DERIVED MACROPHAGES; IFN-Γ; IL; INTERFERON-Γ; INTERLEUKIN; LDL; LDL RECEPTOR; LDLR; LIPOPROTEIN LIPASE; LOW-DENSITY LIPOPROTEIN; LPL; MACROPHAGES; MATRIX METALLOPROTEINASE; MMP; PHORBOL 12-MYRISTATE 13-ACETATE; PMA; REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION; RT-QPCR; TGF-Β; TL1A; TNF-Α; TRANSFORMING GROWTH FACTOR-Β; TUMOUR NECROSIS FACTOR-LIKE PROTEIN 1A; TUMOUR NECROSIS FACTOR-Α; VASCULAR SMOOTH MUSCLE CELLS; VSMC;

ADAM PROTEINS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; MACROPHAGES; MONOCYTES; PLAQUE, ATHEROSCLEROTIC; PROCOLLAGEN N-ENDOPEPTIDASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 84883557821     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.06.315     Document Type: Article

References (58)

1. McLaren J.E., Michael D.R., Ashlin T.G., Ramji D.P. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 2011, 50:331-347.
2. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
3. Halvorsen B., Otterdal K., Dahl T.B., Skjelland M., Gullestad L., Oie E., et al. Atherosclerosis plaque stability - what determines the fate of a plaque?. Prog Cardiovasc Dis 2008, 51:183-194.
4. Salter R.C., Ashlin T.G., Kwan A.P., Ramji D.P. ADAMTS proteases: key roles in atherosclerosis?. J Mol Med (Berl) 2010, 88:1203-1211.
5. Porter S., Clark I.M., Kevorkian L., Edwards D.R. The ADAMTS metalloproteinases. Biochem J 2005, 386:15-27.
6. Tortorella M.D., Malfait F., Barve R.A., Shieh H.S., Malfait A.M. A review of the ADAMTS family, pharmaceutical targets of the future. Curr Pharm Des 2009, 15:2359-2374.
7. Kuno K., Kanada N., Nakashima E., Fujiki F., Ichimura F., Matsushima K. Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem 1997, 272:556-562.
8. Jones G.C., Riley G.P. ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther 2005, 7:160-169.
9. Newby A.C., George S.J., Ismail Y., Johnson J.L., Sala-Newby G.B., Thomas A.C. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost 2009, 101:1006-1011.
10. Wagsater D., Bjork H., Zhu C., Bjorkegren J., Valen G., Hamsten A., et al. ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaques. Atherosclerosis 2008, 196:514-522.
11. Jonsson-Rylander A.C., Nilsson T., Fritsche-Danielson R., Hammarstrom A., Behrendt M., Andersson J.O., et al. Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of versican. Arterioscler Thromb Vasc Biol 2005, 25:180-185.
12. Lee C.W., Hwang I., Park C.S., Lee H., Park D.W., Kang S.J., et al. Comparison of ADAMTS-1, -4 and -5 expression in culprit plaques between acute myocardial infarction and stable angina. J Clin Pathol 2011, 64:399-404.
13. Zha Y., Chen Y., Xu F., Zhang J., Li T., Zhao C., et al. Elevated level of ADAMTS4 in plasma and peripheral monocytes from patients with acute coronary syndrome. Clin Res Cardiol 2010, 99:781-786.
14. Chen L., Yang L., Zha Y., Cui L. Association of serum a disintegrin and metalloproteinase with thrombospondin motif 4 levels with the presence and severity of coronary artery disease. Coron Artery Dis 2011, 22:570-576.
15. Didangelos A., Mayr U., Monaco C., Mayr M. Novel role of ADAMTS-5 protein in proteoglycan turnover and lipoprotein retention in atherosclerosis. J Biol Chem 2012, 287:19341-193445.
16. Salter R.C., Arnaoutakis K., Michael D.R., Singh N.N., Ashlin T.G., Buckley M.L., et al. The expression of a disintegrin and metalloproteinase with thrombospondin motifs 4 in human macrophages is inhibited by the anti-atherogenic cytokine transforming growth factor-beta and requires Smads, p38 mitogen-activated protein kinase and c-Jun. Int J Biochem Cell Biol 2011, 43:805-811.
17. McLaren J.E., Ramji D.P. Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev 2009, 20:125-135.
18. Harvey E.J., Ramji D.P. Interferon gamma and atherosclerosis: pro- or anti-atherogenic?. Cardiovasc Res 2005, 67:11-20.
19. Singh N.N., Ramji D.P. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev 2006, 17:487-499.
20. McLaren J.E., Calder C.J., McSharry B.P., Sexton K., Salter R.C., Singh N.N., et al. The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro. J Immunol 2010, 184:5827-5834.
21. Kang Y., Kim W., Bae H., Kim D., Park Y.B., Park J., et al. Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 2005, 29:229-235.
22. Gu Y., Hu X., Liu C., Qv X., Xu C. Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. British J Haemat 2008, 142:109-114.
23. Taleb S., Tedgui A., Mallat Z. Interleukin-17: friend or foe in atherosclerosis?. Curr Opin Lipidol 2010, 21:404-408.
24. McLaren J.E., Michael D.R., Salter R.C., Ashlin T.G., Calder C.J., Miller A.M., et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010, 185:1222-1229.
25. Michael D.R., Salter R.C., Ramji D.P. TGF-beta inhibits the uptake of modified low density lipoprotein by human macrophages through a Smad-dependent pathway: a dominant role for Smad-2. Biochim Biophys Acta 2012, 1822:1608-1616.
26. Qin Z. The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature. Atherosclerosis 2012, 221:2-11.
27. Worley J.R., Baugh M.D., Hughes D.A., Edwards D.R., Hogan A., Sampson M.J., et al. Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem 2003, 278:51340-51346.
28. Auwerx J.H., Deeb S., Brunzell J.D., Wolfbauer G., Chait A. Lipoprotein lipase gene expression in THP-1 cells. Biochemistry 1989, 28:4563-4567.
29. Basheeruddin K., Rechtoris C., Mazzone T. Transcriptional and post- transcriptional control of apolipoprotein E gene expression in differentiating human monocytes. J Biol Chem 1992, 267:1219-1224.
30. Singh N.N., Ramji D.P. Transforming growth factor-beta-induced expression of the apolipoprotein E gene requires c-Jun N-terminal kinase, p38 kinase, and casein kinase 2. Arterioscler Thromb Vasc Biol 2006, 26:1323-1329.
31. Zuckerman S.H., Evans G.F., O'Neal L. Cytokine regulation of macrophage apoE secretion: opposing effects of GM-CSF and TGF-beta. Atherosclerosis 1992, 96:203-214.
32. Hughes T.R., Tengku-Muhammad T.S., Irvine S.A., Ramji D.P. A novel role of Sp1 and Sp3 in the interferon-gamma-mediated suppression of macrophage lipoprotein lipase gene transcription. J Biol Chem 2002, 277:11097-11106.
33. Brand K., Mackman N., Curtiss L.K. Interferon-gamma inhibits macrophage apolipoprotein E production by post-translational mechanisms. J Clin Invest 1993, 91:2031-2039.
34. Li N., McLaren J.E., Michael D.R., Clement M., Fielding C.A., Ramji D.P. ERK is integral to the IFN-gamma-mediated activation of STAT1, the expression of key genes implicated in atherosclerosis, and the uptake of modified lipoproteins by human macrophages. J Immunol 2010, 185:3041-3048.
35. Patel D.N., King C.A., Bailey S.R., Holt J.W., Venkatachalam K., Agrawal A., et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-κB and C/EBPβ activation. J Biol Chem 2007, 282:27229-27238.
36. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflamattory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998, 160:3513-3521.
37. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012, 122:487-511.
38. Paintlia M.K., Paintlia A.S., Singh A.K., Singh I. Synergistic activity of interleukin-17 and tumor necrosis factor-alpha-enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem 2011, 116:508-521.
39. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
40. Eid R.E., Rao D.A., Zhou J., Lo S.F., Ranjbaran H., Gallo A., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
41. Papadakis K.A., Prehn J.L., Landers C., Han Q., Luo X., Cha S.C., et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 2004, 172:7002-7007.
42. Papadakis K.A., Zhu D., Prehn J.L., Landers C., Avanesyan A., Lafkas G., et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18- induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol 2005, 174:4985-4990.
43. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
44. Jiang X., Zeng H.S., Guo Y., Zhou Z.B., Tang B.S., Li F.K. The expression of matrix metalloproteinase-9, transforming growth factor-beta1 and transforming growth factor-beta receptor 1 in human atherosclerotic plaque and their relationship with plaque stability. Chin Med J (Engl) 2004, 117:1825-1829.
45. Bot P.T., Hoefer I.E., Sluijter J.P., van Vliet P., Smits A.M., Lebrin F., et al. Increased expression of the transforming growth factor-beta signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 2009, 40:439-447.
46. Frutkin A.D., Otsuka G., Stempien-Otero A., Sesti C., Du L., Jaffe M., et al. TGF-beta1 limits plaque growth, stabilizes plaue structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2009, 29:1251-1257.
47. Nareika A., Sundararaj K.P., Im Y.B., Game B.A., Lopes-Virella M.F., Huang Y. High glucose and interferon gamma synergistically stimulate MMP-1 expression in U937 macrophages by increasing transcription factor STAT1 activity. Atherosclerosis 2009, 202:363-371.
48. Newby A.C. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007, 17:253-258.
49. Kim S.H., Lee W.H., Kwon B.S., Oh G.T., Choi Y.H., Park J.E. Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. Jpn Circ J 2001, 65:136-138.
50. Danzaki K., Matsui Y., Ikesue M., Ohta D., Ito K., Kanayama M., et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012, 32:273-280.
51. Usui F., Kimura H., Ohshiro T., Tatsumi K., Kawashima A., Nishiyama A., et al. Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Biophys Res Commun 2012, 420:72-77.
52. Butcher M., Galkina E. Current views on the function of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost 2011, 106:787-795.
53. Taleb S., Romain M., Ramkhelawon B., Uyttenhove C., Pasterkamp G., Herbin O., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009, 206:2067-2077.
54. Butcher M.J., Gjurich B.N., Phillips T., Galkina E.V. The IL-17A/IL- 17RA axis plays a proatherogenic role via regulation of aortic myeloid cell recruitment. Circ Res 2012, 110:675-687.
55. Cheng X., Taleb S., Wang J., Tang T.T., Chen J., Gao X.L., et al. Inhibition of IL-17A in atherosclerosis. Atherosclerosis 2011, 215:471-474.
56. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003, 14:155-174.
57. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., Idu M.M., van Maldegem F., et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010, 220:499-508.
58. Wang L., Zheng J., Bai X., Liu B., Liu C., Xu Q., et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in ballon-injured rat arteries. Circ Res 2009, 104:688-698.